Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic ...

The incidence and mortality rate of esophageal cancer in China fell by around 4.5 percent annually, according to the figures ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 Overlooked Growth Stocks to Buy Now. Zai Lab Limited (NASDAQ:ZLAB) is one of ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...

Early results presented at a cancer research conference showed tumor shrinkage and slowed disease progression in patients who ...

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS® (zongertinib tablets) in treatment-naïve ...

In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory ...